The US Food and Drug Administration (FDA) has approved Emflaza (deflazacort) tablets and oral suspension to treat patients aged ≥5 years with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is marketed by Marathon Pharmaceuticals of Northbrook, IL.
Indications: Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.
Dosage/administration: Emflaza is administered orally by tablet; it is available in 6 mg, 18 mg, 30 mg, and 36 mg (oral suspension: 22.75 mg/mL). The recommended once-daily dosage is approximately 0.9 mg/kg/day. Discontinue gradually when administered for more than a few days.
Adverse effects: The most common adverse reactions (≥ 10% for Emflaza and greater than placebo) are Cushingoid appearance, weight increase, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.
US Food and Drug Administration. FDA approves drug to treat Duchenne muscular dystrophy. FDA Web site. February 9, 2017. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm540945.htm. Accessed February 13, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23